Related Experiment Video

Updated: Jul 15, 2026

Ferric Chloride-induced Murine Thrombosis Models
10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

The pharmacogenetics of antiplatelet drugs

Francisco Marín1, Vanessa Roldán, Rocío González-Conejero

  • 1Servicio de Cardiologia, Hospital Universitario Virgen de la Arrixaca, Madrid-Cartagen s/n El Palmar, Murcia, 30008 Spain. fcomarino@hotmail.com

Current Opinion in Investigational Drugs (London, England : 2000)
|April 6, 2007
PubMed

Insights

Genetic variations affect how well antiplatelet drugs work for preventing heart attacks and strokes. Understanding these pharmacogenetics can personalize treatment for better cardiovascular disease outcomes.

Area of Science:

  • Cardiovascular Medicine
  • Pharmacogenetics
  • Genetics

Background:

  • Platelets are crucial in coronary heart disease and atherothrombotic events.
  • Antiplatelet therapy is a common treatment for cardiovascular disease, but its effectiveness varies.
  • Many patients experience recurrent thrombotic events despite antiplatelet treatment.

Purpose of the Study:

  • To explore the influence of genetic variations on antiplatelet drug efficacy.
  • To identify specific gene polymorphisms that modulate individual responses to antiplatelet therapy.
  • To explain the heterogeneity observed in patient responses to antiplatelet drugs.

Main Methods:

  • Review of existing literature on pharmacogenetics and antiplatelet therapy.
  • Analysis of genetic polymorphisms and their association with antiplatelet drug response.
  • Exploration of how genetic factors contribute to treatment variability.

Main Results:

  • Individual responses to antiplatelet drugs are significantly influenced by genetic factors.
  • Specific genetic polymorphisms have been identified that affect drug metabolism and platelet inhibition.
  • Pharmacogenetic testing may help predict patient response to antiplatelet therapy.

Conclusions:

  • Genetic variations play a key role in the efficacy of antiplatelet therapy.
  • Personalized antiplatelet treatment based on pharmacogenetics could improve patient outcomes.
  • Further research is needed to fully elucidate the genetic underpinnings of antiplatelet drug response.

More Related Videos

Microfluidics in Assessing Platelet Function06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Pharmacogenetics and Pharmacogenomics: Overview01:29

Pharmacogenetics and Pharmacogenomics: Overview

Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...